pmlive.com
Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease
A new FDA approval expands treatment options for adults with moderately to severely active Crohn’s disease, including a fully subcutaneous IL-23 inhibitor regimen that could offer more flexibility. The approval was based on phase 3 trials and may be relevant for people who failed or were intolerant to prior therapies.
Adults with Crohn’s disease, patients who have failed or are intolerant to other biologics or conventional therapies, clinicians treating IBD, and researchers following new IBD drug approvals.
What To Know
Johnson & Johnson’s Tremfya (guselkumab) has received FDA approval for adults with moderately to severely active Crohn’s disease.
The article highlights that Tremfya is an IL-23 inhibitor available with both subcutaneous and intravenous induction options, and that approval was supported by multiple phase 3 trials (the GRAVITI programme is named) involving patients who failed or were intolerant to conventional therapy or biologics.
It also notes prior US approvals of Tremfya for ulcerative colitis, plaque psoriasis, and psoriatic arthritis, and mentions a comparison to ustekinumab in pooled endoscopic endpoints. The FDA has approved guselkumab (Tremfya) for adults with moderately to severely active Crohn’s disease.
The company emphasizes the availability of a fully subcutaneous induction regimen as a new option. The approval is based on phase 3 trial data including more than 1,300 patients and the GRAVITI programme, per the article. The piece quotes investigators and company representatives describing endoscopic remission outcomes and treatment flexibility.
Practical points: This is regulatory news about a newly approved treatment option; it does not provide prescribing guidance, safety details, or head-to-head comparative effectiveness data beyond the article’s mention of pooled trial endpoints.
Patients should discuss with their gastroenterology team whether this option is appropriate for their individual disease history and prior treatments.
This article reports regulatory approval and summarizes trial program names and company statements. It does not include detailed safety data, full trial results, or prescribing information. New approvals can affect access and insurance coverage, but individual suitability and timing of use depend on clinician judgement and local formularies.